Ajay Devgn Bombay High Court: Challenges Vimal Notice From FDA

• Bollywood actor Ajay Devgn has challenged a Maharashtra FDA show-cause notice in the Bombay High Court.
• The notice alleges his 'Vimal Elaichi' ads are surrogate promotions for 'Vimal Pan Masala', a product banned in Maharashtra.
• Similar notices were also issued to co-brand ambassadors Shah Rukh Khan and Tiger Shroff.
• Devgn's petition questions the constitutionality of FDA regulations and argues he was arbitrarily targeted over the manufacturing company.
• The manufacturer, PB Agro, previously had its plea dismissed by the Delhi High Court due to lack of territorial jurisdiction.

This case highlights the increasing regulatory scrutiny on brand ambassadors for surrogate advertising of banned products, placing individual celebrities under direct legal challenge.

Bollywood actor Ajay Devgn has initiated legal proceedings in the Bombay High Court, contesting a show-cause notice issued by the Maharashtra Food and Drugs Administration (FDA). This action, formally titled "Ajay Devgan v. State of Maharashtra & Ors.", directly challenges the regulatory body's directive concerning his involvement in advertisements for 'Vimal Elaichi'. The petition is slated for a hearing on November 4 before a division bench comprising Chief Justice Mahesh C Tripathi and Justice Advait Sethna. The core of the dispute revolves around the FDA's assertion that the 'Vimal Elaichi' campaigns function as a form of surrogate promotion for 'Vimal Pan Masala', a chewable product that is currently prohibited from sale within the state of Maharashtra. Notices of a similar nature have also been dispatched to fellow brand ambassadors, Shah Rukh Khan and Tiger Shroff, indicating a broader regulatory focus on celebrity endorsements for such products.

The Maharashtra FDA's intervention underscores a growing concern regarding surrogate advertising, particularly when it involves products like 'Vimal Pan Masala' that face outright bans. The regulatory body maintains that by promoting 'Vimal Elaichi', the advertisements indirectly encourage the consumption of the banned pan masala, circumventing existing public health regulations. This case highlights the increasing regulatory scrutiny on brand ambassadors for surrogate advertising of banned products, placing individual celebrities under direct legal challenge. The FDA's stance suggests a move towards holding public figures accountable for the products they endorse, especially when those products are linked to items with health concerns or legal restrictions. This development could set a precedent for how celebrity endorsement deals are structured and evaluated for compliance risks in India.

Prior to Devgn's current legal move, the manufacturer of the product, PB Agro, had sought relief from the Delhi High Court in August, aiming to quash the very same notices. However, that plea was dismissed, with the Delhi High Court determining it lacked territorial jurisdiction. The court clarified that since the controversy stemmed from actions taken by the Mumbai FDA pertaining to alleged activities within Maharashtra, the appropriate legal forum would be the courts within that state. Following this jurisdictional ruling, Ajay Devgn proceeded to file his petition with the Bombay High Court. In his legal challenge, Devgn's DSK legal team argues against the constitutionality of the specific provisions within the FDA regulations. Furthermore, he contends that the notice was arbitrarily directed at him as an actor, rather than being served upon the manufacturing company responsible for the product itself. This argument points to a potential shift in liability, moving from corporate entities to individual endorsers, and is a key aspect of the Ajay Devgn Bombay High Court Vimal notice challenge.

This case highlights the increasing regulatory scrutiny on brand ambassadors for surrogate advertising of banned products. Lawyers advising celebrities or companies on endorsement deals should assess potential liabilities for individuals and ensure contracts address regulatory compliance risks, particularly regarding products with regional sales restrictions or health concerns.

Source: Original reporting via legal news outlet.